- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
- Paralegals
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
September 12, 2023Annie Huang Receives Asian Leadership Award from Profiles in Diversity Journal
-
September 12, 2023Robins Kaplan Partners Named to 2024 Lawdragon 500 Leading Litigators in America Guide
-
September 11, 2023Robins Kaplan Names Brendan Johnson Chair of National Business Litigation Group
-
September 26-28, 20236th Annual LF Dealmakers Forum
-
September 28-29, 20232023 Midwest IP Institute
-
October 27, 2023LGBTQ Legal Services: Transgender Name Change Clinic
-
August 21, 2023Colorado Expands Antitrust Protection
-
July 18, 2023Copyright: Rights Even Heroes Can't Protect
-
August 2023Minnesota Bans Non-Competes Formed on or After July 1, 2023: Assessing Remaining Strategies to Protect Confidential Information and Trade Secrets
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Professionals
Christopher A. Pinahs
Partner
Christopher P. Sullivan
Partner
Matthew P. Cardosi
Associate
Alice Mendelsohn Ribbens, Ph.D.
Senior Scientist
Related Publications
July 7, 2023
PTAB Overruled: A New Analysis For Real Party In Interest
Derrick Carman - Law360
April 20, 2023
Drafting Subsequent Agreements to Avoid Arbitrability Litigation
David Prange, Benjamen Linden, Michael Longley - Bloomberg Law
April 12, 2023
Statute of Limitations is a Key Issue in Delaware Trade Secret Dispute
Sharon Roberg-Perez - IAM
March 2023
Unintended Consequences of Banning Noncompete Agreements
Michael Geibelson, Stephen Safranski, Michael Pacelli - Bloomberg Law
March 26, 2023
What I’ll Be Watching for in the Amgen Oral Arguments
Jake Holdreith - IPWatchdog
Related News
September 12, 2023
July 5, 2023
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.